Davide Ciardiello - Concepedia

Author

Davide Ciardiello

University of Campania "Luigi Vanvitelli"ORCID

Also Known As

Ciardiello Davide, Ciardiello, Davide, D. Ciardiello, Davide Ciardiello

191

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

University of Campania "Luigi Vanvitelli"Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Casa Sollievo della Sofferenza Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori

About

Davide Ciardiello is an author at University of Campania "Luigi Vanvitelli" specializing in oncology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	302
2	Immunology	4	4	107
3	Cell Biology	3	3	123
4	Gastroenterology	2	2	21
5	Health Sciences	1	1	36

Davide Ciardiello

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer Erika Martinelli, Giulia Martini, Vincenzo Famiglietti, JAMA Oncology	2021	174
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition Teresa Troiani, Stefania Napolitano, Donata Vitagliano, Clinical Cancer Research	2014	100
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Journal of Experimental & Clinical Cancer Research	2019	87
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello, Molecular Cancer Therapeutics	2019	84
AXL is an oncotarget in human colorectal cancer Erika Martinelli, Giulia Martini, Claudia Cardone, Oncotarget Tumor BiologyOncogenic AgentMedicineColorectal CancerPathology	2015	64
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study Yoshinori Kagawa, Élena Elez, Jesús García‐Foncillas, Clinical Cancer Research	2021	64
Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab Giulia Martini, Davide Ciardiello, Marcello Dallio, International Journal of Cancer DysbiosisAntitumor ActivityImmunologyPathologyGut Microbiota	2022	61
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer Claudia Cardone, Bernadette Blauensteiner, Verónica Moreno‐Viedma, European Journal of Cancer MedicinePathologyColorectal CancerAnti-egfr TherapyCancer Biology	2020	48
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression Stefania Napolitano, Nunzia Matrone, A. L. Muddassir, Journal of Experimental & Clinical Cancer Research	2019	38
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer Pietro Paolo Vitiello, Giulia Martini, Luigi Mele, Journal of Experimental & Clinical Cancer Research	2021	37

Page 1